Solriamfetol in excessive daytime sleepiness: a profile of its use

Compliance with Ethical Standards

Disclosure: The preparation of this review was not supported by any external funding.

Conflicts of interest: Emma Deeks and Young-A Heo are salaried employees of Adis International Ltd./Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found here

Abstract

Oral solriamfetol (Sunosi™), a selective dopamine and norepinephrine reuptake inhibitor, is approved to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnoea (OSA) in the USA and EU. In phase 3 trials in patients with narcolepsy or OSA, relative to placebo, solriamfetol within the recommended dosage for narcolepsy (75–150 mg/day) or OSA (37.5–150 mg/day) improved wakefulness and reduced sleepiness, together with patient- and clinician-rated global improvements. The clinical benefits of solriamfetol were maintained with longer-term treatment. Solriamfetol is generally well tolerated, with most adverse events being of mild to moderate severity.